chemoimmunotherapy in tnbc: the keynote-355 trial
Published 5 years ago • 457 plays • Length 4:53Download video MP4
Download video MP3
Similar videos
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
5:37
researcher comment: the keynote-355 trial | javier cortes
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
2:07
tnbc: using checkpoint inhibitors alone or with chemotherapy
-
2:00
pembrolizumab plus chemotherapy show efficacy for tnbc in keynote-355
-
8:42
chemoimmunotherapy in tnbc: the impassion130 trial
-
1:43
dr. rugo on the results of the keynote-522 trial in tnbc
-
4:11
asco 2020: pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast c...
-
1:01
chemo-immunotherapy for tnbc
-
2:06
dr. schmid on the design and findings of the keynote-173 trial in tnbc
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
2:24
keynote-355: pembrolizumab in triple-negative breast cancer
-
1:35
longer overall survival in metastatic tnbc with pembrolizumab - medpage today
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
4:54
hope rugo, md, shares the design and outcomes of keynote-355 presented at sabcs 2020
-
3:26
chemo-immunotherapy for tnbc
-
4:17
treatment options in metastatic tnbc